Shares of Mankind Pharma surged more than 3% in early trade on Wednesday after the company reported a strong set of Q4FY26 earnings, driven by healthy revenue growth, sharp margin expansion, and robust profit performance.
For the quarter ended March 2026, the pharmaceutical major reported revenue of Rs 3,443 crore, marking an increase of 11.8% year-on-year compared to Rs 3,079 crore in the corresponding quarter last year.
The company’s EBITDA rose 36.1% YoY to Rs 930 crore against Rs 683 crore in Q4FY25. EBITDA margin improved significantly to 27.0% from 22.2% a year ago, indicating strong cost control and better operating leverage.
Net profit for the quarter came in at Rs 554 crore, up 31.7% from Rs 421 crore reported in the year-ago period.
Mankind Pharma Share Price Performance
At 10 AM, Mankind Pharma shares were trading over 3% higher for the day.
The stock touched an intraday high of Rs 2,579.50, while the day’s low stood at Rs 2,500.00. The stock opened at Rs 2,501.00 compared to its previous close of Rs 2,492.60.
Trading activity remained strong with live volume at 12,78,779 shares.
On a broader basis, the stock has a 52-week high of Rs 2,716.50 and a 52-week low of Rs 1,909.70.